Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized
by the progressive death of dopaminergic neurons in the substantia nigra pars compacta (SNc).
PD is a multifactorial disorder, with several different factors being suggested to play a synergistic
pathophysiological role, including oxidative stress, autophagy, underlying pro-inflammatory events
and neurotransmitters abnormalities. Overall, PD can be viewed as the product of a complex interaction
of environmental factors acting on a given genetic background. The importance of this subject has
gained more attention to discover novel therapies to prevent as well as treat PD. According to previous
research, drugs used to treat PD have indicated significant limitations. Therefore, the role of flavonoids
has been extensively studied in PD treatment. Quercetin, a plant flavonol from the flavonoid
group, has been considered as a supplemental therapy for PD. Quercetin has pharmacological functions
in PD by controlling different molecular pathways. Although few studies intended to evaluate
the basis for the use of quercetin in the context of PD have been conducted so far, at present, there is
very little evidence available addressing the underlying mechanisms of action. Various principal aspects
of these treatment procedures remain unknown. Here, currently existing knowledge supporting
the use of quercetin for the clinical management of PD has been reviewed.